The Texas Heart Institute’s Drs Salim Virani and Matthew Segar look back at the history of SGLT2 inhibitors, which have roots in a fascinating FDA initiative focused on cardiovascular outcomes in diabetes medications. They explore the serendipitous beginnings of these groundbreaking medicines and their significant impact on cardiovascular health.

Watch this episode on Texas Heart TV  

Allan Zhang, Ramsey Kalil, Alexander Marzec, Stephanie A. Coulter, Salim Virani, Kershaw V. Patel, Matthew W. Segar; Cardiovascular Disease Management With Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes: A Cardiology Primer. Tex Heart Inst J 1 January 2024; 51 (1): e238375. doi: https://doi.org/10.14503/THIJ-23-8375

Watch On Demand Videos on Texas Heart TV

Visit Our Website: texasheart.org